Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Encompass Health Corporation due to allegations of materially misleading business information [1] Group 1: Investigation and Allegations - The investigation is prompted by an article from The New York Times highlighting serious incidents of patient harm and below-average performance on key safety measures at Encompass Health's rehab hospitals [3] - Following the publication of the article, Encompass Health's stock price dropped by 10.3% on July 15, 2025 [3] Group 2: Class Action Details - Investors who purchased Encompass Health securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2] - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4] - The firm has been ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 [4]

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of LifeMD, Inc. securities between May 7, 2025, and August 5, 2025, due to alleged misleading statements and failure to disclose critical information regarding the company's competitive position and customer acquisition costs [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that LifeMD's defendants made materially false and misleading statements about the company's competitive position and financial guidance, particularly regarding customer acquisition costs in the RexMD segment and the sale of obesity treatment drugs [5]. - Investors who purchased LifeMD securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by October 27, 2025, to represent other class members in the litigation [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Encompass Health Corporation due to allegations of materially misleading business information issued to the public [1] Group 1: Investigation and Allegations - The investigation is prompted by an article published by The New York Times on July 15, 2025, which highlighted serious incidents of patient harm and below-average performance on key safety measures at Encompass Health's rehab hospitals [4] - Following the publication of the article, Encompass Health's stock price experienced a significant decline of 10.3% on the same day [4] Group 2: Class Action and Compensation - Shareholders who purchased Encompass Health securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees or costs due to a contingency fee arrangement [2] - Interested parties can join the prospective class action by submitting a form or contacting the Rosen Law Firm directly [3] Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and consistently ranking in the top 4 for securities class action settlements since 2013 [5] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [5]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Quantum Corporation due to allegations of materially misleading business information [1] Group 1: Investigation and Legal Action - Shareholders of Quantum Corporation may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2] - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2] Group 2: Company Developments - On August 18, 2025, Quantum Corporation's CFO, Lewis Moorehead, resigned amid an internal accounting review related to revenue recognition practices [3] - Following the announcement of the CFO's resignation, Quantum's stock price fell by $0.61 per share, or 8.2%, closing at $6.83 per share on August 19, 2025 [3] Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4] - The firm has been ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Fiserv, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the Fiserv common stock is from July 24, 2024, to July 22, 2025, inclusive [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A lead plaintiff must file a motion with the Court by September 22, 2025, to represent other class members [2] Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has consistently ranked in the top 4 for securities class action settlements since 2013, recovering hundreds of millions for investors [3] Group 3: Case Allegations - The lawsuit alleges that Fiserv made false and misleading statements regarding its Clover platform and the forced migration of Payeezy merchants [4] - It is claimed that Clover's revenue growth was artificially inflated due to these forced conversions, masking a slowdown in new merchant business [4] - The lawsuit asserts that many former Payeezy merchants switched to competitors due to Clover's high pricing and compatibility issues, leading to a significant slowdown in Clover's growth [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Hims & Hers Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the lawsuit is from April 29, 2025, to June 23, 2025 [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by August 25, 2025, to serve as lead plaintiff [2] Group 2: Legal Representation - Investors are encouraged to select qualified counsel with a successful track record in securities class actions [3] - Rosen Law Firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [3] - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3] Group 3: Case Allegations - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, affecting investor decisions [4] - Specific claims include the failure to disclose the nature of the collaboration with Novo and the availability of weight-loss drug Wegovy for Hims subscribers [4] - The lawsuit asserts that when the true details were revealed, investors suffered damages [4]

Core Viewpoint - A securities class action lawsuit has been filed against KinderCare Learning Companies, Inc. regarding its October 2024 IPO, alleging misleading disclosures about the quality of care and education provided by the company [1][3]. Company Overview - KinderCare Learning Companies, Inc. is the largest provider of early childhood education in the United States, with over 30% of its revenues derived from federal subsidies, primarily through the Child Care Development Fund [2]. IPO Details - KinderCare priced 27 million shares at $24 per share during its IPO on October 8, 2024, raising total gross proceeds of $648 million [3]. Allegations and Concerns - The lawsuit claims that KinderCare's offering documents falsely assured investors of "high-quality" care, while failing to disclose significant issues, including numerous incidents of child abuse and neglect at its facilities [4][6]. - Reports published by analyst Edwin Dorsey highlighted serious allegations against KinderCare, including unsafe conditions for children and a lack of accountability, which have led to a significant decline in share price since the IPO [5][6]. Financial Performance - Following the IPO, KinderCare has reported disappointing financial results, citing softening or declining enrollment, which has further impacted its stock price [5].

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety of its gene therapy drug, ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [1][2]. Allegations - The lawsuit claims that Sarepta failed to disclose significant safety risks associated with ELEVIDYS, including the inability of trial protocols to detect severe side effects and the potential for adverse events to halt recruitment and dosing in clinical trials [2]. Stock Price Impact - Following a safety update on March 18, 2025, which reported a patient death after ELEVIDYS treatment, Sarepta's stock price dropped by $27.81, or 27.44%, closing at $73.54 [3]. - On June 15, 2025, after disclosing a second patient death due to acute liver failure and announcing a suspension of shipments for non-ambulatory patients, the stock fell by $15.24, or 42.12%, to close at $20.91 [3]. - The FDA's investigation announcement on June 24, 2025, regarding the risk of acute liver failure led to an additional stock price decline of $1.52, or 8.01%, closing at $17.46 [4]. Class Action Participation - Shareholders interested in participating as lead plaintiffs in the class action must file a motion by August 25, 2025, although they can remain absent class members without taking action [5].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Lineage, Inc. common stock related to its July 2024 IPO, alleging that the registration statement was misleading and failed to disclose critical information about the company's financial health and market conditions [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Lineage was experiencing a decline in customer demand due to increased cold-storage supply and a shift in customer inventory strategies post-COVID-19, which was not disclosed in the registration statement [5]. - It is alleged that Lineage had implemented unsustainable price increases prior to the IPO, which could not be maintained in the face of weakening demand [5]. - The lawsuit asserts that Lineage was unable to counteract adverse market trends through operational efficiencies or competitive advantages, leading to stagnant or declining revenue, occupancy rates, and rent prices [5]. Group 2: Investor Information - Investors who purchased Lineage common stock may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6]. - A lead plaintiff is needed to represent the class, and interested parties must move the court by September 30, 2025 [1][3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Reddit, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on August 18, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - The class action lawsuit has been filed against Reddit, Inc. for allegedly making false and misleading statements regarding user engagement and advertising revenues during the Class Period [4]. - Investors who purchased Reddit securities between October 29, 2024, and May 20, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2]. Group 2: Allegations Against Reddit - The lawsuit claims that changes in Google Search's algorithm led to a significant reduction in traffic to Reddit, as users were able to find answers directly from Google without visiting Reddit [4]. - It is alleged that Reddit's management was aware of these changes and their impact on user engagement but failed to disclose this information, leading to an unrealistic outlook on user rates and advertising revenues [4]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has consistently ranked in the top 4 for securities class action settlements since 2013 [3].